Somnomed Limited · ASX:SOM
Somnomed — H1 FY25 Earnings Presentation
19 slides from Somnomed's earnings presentation, February 2025
Slide 1: Investor Presentation Half Year 2025 Results
Investor Presentation Half Year 2025 Results February 2025 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about SomnoMed Limited’s (the Company’s) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document
Slide 3: Overview – H1 FY25
Overview – H1 FY25
Slide 4: H1 FY25 results snapshot
H1 FY25 results snapshot Revenue EBITDA1 Cash $53.7m $5.8m $18.5m +19% vs pcp2 $45.1m vs pcp ($1.1m) +14% vs 30 June 2024 of $16.2m Positive operating cash flow $4.1m and free cash flow $1.3m, +$8.7m and +$9.3m vs pcp, respectively Figures throughout presentation are denominated in AUD, unless other
Slide 5: Building the foundations for profitable growth
Building the foundations for profitable growth 3-year priorities FY25 Jan 2024 – Jun 2024 Sustainable growth and innovation Execution and Reset delivery • Return to double digit revenue growth ✓ People and culture: build a high • 10%+ EBITDA1 margins performing team and culture of • Rest Assure® lau
Slide 6: Overview – H1 FY25
Overview – H1 FY25 1. Financial information 2. Operations update 3. FY25 outlook
Slide 7: Group revenue +19% vs pcp with significant margin improvement
Group revenue +19% vs pcp with significant margin improvementGroup revenue and growth +19% $54m $45m Revenue growth • Revenue growth of +19% H1 FY25 vs H1 FY24 • Double digit growth across all regions +20% +18% $28m Earnings growth $25m $24m • EBITDA1 is $6.9m higher than pcp, with $21m margin impro
Slide 8: Regional highlights
Regional highlights Total regional revenue Europe North America APAC • Strong demand facilitated by +11% improved turnaround times $28m resulting in double digit growth across all regions $25m +32% $22m • North American growth from all customer segments, with new customer entry particularly $17m buo
Slide 9: Profit and loss summary
Profit and loss summary Revenue $m H1 FY25 H1 FY24 % • Double digits growth across all regions Revenue 53.7 45.1 19% • Driven by continued production turn around Gross margin 33.1 28.1 18% time improvements and robust overall demand Sales and marketing expenses (11.0) (13.7) (20%) Administrative exp
Slide 10: Balance sheet summary
Balance sheet summary $m 31 December 2024 30 June 2024 Cash and cash equivalents 18.5 16.2 Cash and cash equivalents • Increased balance sheet strength Trade and other receivables 16.2 12.4 Inventories 6.7 6.3 Property, plant and equipment 5.8 5.8 Intangible assets 20.3 20.3 Right of use asset 4.6 5
Slide 11: Cash flow summary
Cash flow summary $m H1 FY25 H1 FY24 EBITDA1 5.8 (1.1) Movement in working capital and other (1.5) (1.7) non-cash Tax paid (0.3) (0.7) Interest • Reduced interest charges following Net finance costs paid (0.0) (1.1) repayment of primary debt facility in Q4 Operating cash flow 4.1 (4.6) FY24 prior ye
Slide 12: Overview – FY25
Overview – FY25 1. Financial information 2. Operations update 3. FY25 outlook
Slide 13: Manufacturing highlights – latest results
Manufacturing highlights – latest results Capacity Turnaround Backlog time Manufacturing capacity uplift Manufacturing production Manufacturing production by >40% turnaround time reduced backlog from >2 weeks to <2 from >3 weeks to <10 days days Investing to make operations sustainable 13 © February
Slide 14: New leadership team members
New leadership team members Jonathan Vowels: VP Manufacturing and Operations • Former Operations Director SEA British American Tobacco • Over 25 years manufacturing and supply chain experience Ye-Fei Guo: Chief Financial Officer • Former VP Finance at Brookfield, trained at PwC • CA, over 20 years i
Slide 15: Sector, manufacturing and investment experience added to Board
Sector, manufacturing and investment experience added to Board Andrew Price • Former ResMed Chief Supply Chain Officer • Over 25 years medical devices experience • Led end to end supply chain, including supplier management, manufacturing, logistics, distributions, quality assurance and regulatory af
Slide 16: Rest Assure® status Feb 2025
Rest Assure® status Feb 2025 • FDA cleared Rest Assure® as the first oral device with built-in compliance monitoring • Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems Rest Assure® next steps • New FDA 510k submission u
Slide 17: Overview – FY25
Overview – FY25 1. Financial information 2. Operations update 3. FY25 outlook
Slide 18: FY25 guidance
FY25 guidance Upgrade Upgrade Original Nov24 Jan25 Revenue c. $100m c. $105m c. $105m EBITDA1 >$5m >$7m $7-9m Capex $3-4m $3-4m $3-4m 18 © February 2025 SomnoMed
Slide 19: For further information please contact:
For further information please contact: Investor Relations: IR@somnomed.com.au © February 2025 SomnoMed 19